The peptide potentiated F508del-CFTR and was significantly more efficient than the gold-standard CFTR potentiator VX-770 both in bronchial monolayers and in intestinal organoids from F508del patients. Furthermore, the peptide improved F508del-CFTR conductance even after chronic Orkambi®, without interfering with channel stability. On the contrary, the peptide per se ameliorated F508del-CFTR stability at the plasma membrane. The PI3Kγ-derived peptide is covered by patent number TO2014A00110 – WO/2016/103176 and received the Orphan Drug Designation by the European Medicinal Agency (EU/3/17/1859) in 2017. Researchers intend to develop the PI3Kγ peptide as a novel medicinal product that could be used, either alone or in combination with gold-standard therapies, in F508del patients. With the Extension project FFC#11/2017 they intend to complete the chemical optimization and the characterization of the therapeutic potential of PI3Kγ peptides (parent and optimized) in CF relevant models.